US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRO Concept

1,137.00

-33.6232-2.87%

Number of Gainers:- -

Number of Losers:2

Number of Flat:1

PE:- -

High:1,166.65

Open:1,166.65

Low:1,116.46

Close:1,170.61

Loading ...

Regeneron CRL for Eylea extension not surprising, says Oppenheimer

Charles River Laboratories International Inc : Jefferies Cuts Target Price to $100 From $169

THOMSON REUTERS

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025

Charles River price target raised to $118 from $101 at Baird

Charles River Laboratories International Inc : Baird Raises Target Price to $118 From $101

THOMSON REUTERS

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?

Lisata Therapeutics Announces Research License with Catalent

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

Equity Markets Rise as Investors Respond to Tariff News

MT Newswires Live

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

FDA reducing animal testing presents overhang for Charles River, says TD Cowen

Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?

Charles River price target lowered to $145 from $160 at Barclays

Positive Investment Outlook for IQVIA Holdings Amidst Market Challenges

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4530/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4530","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","market":"US","secType":"PLATE","nameCN":"CRO Concept","latestPrice":1136.9907,"timestamp":1745263696869,"preClose":1170.6139,"halted":0,"volume":2406750,"delay":0,"changeRate":-0.028723,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-33.623169,"latestTime":"04-21 15:28:17 EDT","open":1166.6467,"high":1166.6467,"low":1116.4567,"amount":292337878.700216,"amplitude":0.042875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.284096,"peRate":22.428648,"turnoverRate":0.010942,"increases":0,"decrements":2,"flats":0,"marketCap":29701906432,"floatMarketCap":28955555328},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","high":1166.6467,"amplitude":0.042875,"preClose":1170.6139,"low":1116.4567,"pbRate":"3.284096","latestPrice":1137.0001,"volume":2406883,"delay":0,"open":1166.6467,"prevYearClose":1673.3123,"prevWeekClose":1170.6139,"prevMonthClose":1472.5228,"prevQuarterClose":1472.5228,"fiveDayClose":1169.5568,"twentyDayClose":1569.1759,"sixtyDayClose":1702.9987,"secType":"PLATE","market":"US","turnoverRate":0.010943,"peRate":22.428648,"marketCap":29702152192,"floatMarketCap":28955798016,"timestamp":1745263699065,"nameCN":"CRO Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4530\",,,,undefined,":{"bkCode":"BK4530","up":0,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4530\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529471800","title":"Regeneron CRL for Eylea extension not surprising, says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529471800","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529471800?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:10","pubTimestamp":1745244617,"startTime":"0","endTime":"0","summary":"Oppenheimer keeps an Outperform rating on Regeneron (REGN) with a $925 price target after the FDA denied the company’s attempt to extend the dosing...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-crl-for-eylea-extension-not-surprising-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-crl-for-eylea-extension-not-surprising-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4530","LU0053666078.USD","LU2106854487.HKD","LU0823416689.USD","LU2023250504.SGD","BK4121","LU0320765992.SGD","LU2089984988.USD","LU2362541513.USD","LU0882574055.USD","LU0109394709.USD","LU2362541273.HKD","OPY","LU0757428866.USD","LU1917777945.USD","BK4585","LU2362540622.SGD","LU2468319806.SGD","BK4139","LU0889565916.HKD","BK4588","LU0114720955.EUR","LU1815336091.USD","REGN","LU1974910355.USD","LU2237438978.USD","LU0390134368.USD","BK4127","LU0289739699.SGD","LU0058720904.USD","CRL"],"gpt_icon":0},{"id":"2529845834","title":"Charles River Laboratories International Inc : Jefferies Cuts Target Price to $100 From $169","url":"https://stock-news.laohu8.com/highlight/detail?id=2529845834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529845834?lang=en_us&edition=fundamental","pubTime":"2025-04-21 12:59","pubTimestamp":1745211591,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ041:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0390134368.USD","BK4530","BK4585","LU0757428866.USD","BK4121","CRL","LU1815336091.USD","BK4588"],"gpt_icon":0},{"id":"2528013715","title":"Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2528013715","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528013715?lang=en_us&edition=fundamental","pubTime":"2025-04-19 03:00","pubTimestamp":1745002800,"startTime":"0","endTime":"0","summary":"TARRYTOWN, N.Y., April 18, 2025  -- Regeneron Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has issued a complete response letter  regarding the supplemental Biologics License Application  for the addition of extended dosing intervals  for EYLEA HD  Injection 8 mg across all approved indications.EYLEA HD is approved with dosing intervals from every 8 to 16 weeks for patients with wet age-related macular degeneration  and diabetic macular edema , and every 8 to 12 weeks for patients with diabetic retinopathy , following 3 initial monthly doses.About Ophthalmology Development at Regeneron At Regeneron, we relentlessly pursue groundbreaking innovations in eye care science to help maintain the eye health of the millions of Americans impacted by vision-threatening conditions. Our expertise in angiogenesis and decades of research serve as our foundation, fueling our ongoing ambition to further innovate new solutions for patients. Our robust and diverse re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-provides-eylea-hd-aflibercept-190000362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4530","LU2468319806.SGD","BK4023","LU0082616367.USD","LU1551013425.SGD","LU1951198990.SGD","BK4532","CRL","IE0009356076.USD","IE00BKVL7J92.USD","LU1951200564.SGD","LU0079474960.USD","LU1917777945.USD","LU0868494708.USD","LU1316542783.SGD","ROP","LU0198837287.USD","IE00BQXX3F31.USD","LU2506951958.HKD","LU0109392836.USD","LU0058720904.USD","LU1242518931.SGD","LU1929549753.HKD","BK4612","BK4206","IE00BSNM7G36.USD","IE00BMPRXR70.SGD","SG9999001440.SGD","LU1430594728.SGD","LU2098885051.SGD","BK4533","LU0354030438.USD","LU0889565916.HKD","LU0127658192.USD","LU1778281490.HKD","BK4534","REGN","LU2458330169.SGD","BK4605","LU1303367103.USD","LU2264538146.SGD","LU1880398471.USD","LU1988902786.USD","LU0234572021.USD","BK4581","LU0950375773.USD","BK4575","HD","LU0823411888.USD"],"gpt_icon":1},{"id":"2528085255","title":"Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528085255","media":"Insider Monkey","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528085255?lang=en_us&edition=fundamental","pubTime":"2025-04-18 11:01","pubTimestamp":1744945314,"startTime":"0","endTime":"0","summary":"We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Charles River Laboratories International, Inc.  stands against other mid-cap stocks insiders were buying in Q1 2025.Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing concerns over ever-changing tariffs. The broader market index dropped 2.2%, the blue-chip companies fell by almost 700 points, a decline of 1.7%, and the Nasdaq Composite —dominated by tech—plunged nearly 3.1%. With this decline, the Nasdaq is now about 19% below its recent peak, edging closer to bear market territory.Stocks dropped to their lowest levels of the day Wednesday after Fed Chair Jerome Powell warned that the tariffs could increase short-term inflation. He noted the Federal Reserve might face a tough situation where its goals of full employment and stable prices may come into conflict, according to CNBC.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/charles-river-laboratories-international-inc-030154003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0757428866.USD","COMP","US7Y.BOND","US6M.BOND","US12M.BOND","BK4588","CRL","US10Y.BOND","BK4539","LU1815336091.USD","US5Y.BOND","BK4121","BK4079","BK4585","BK4530","LU0390134368.USD","US2Y.BOND","US30Y.BOND","US3Y.BOND"],"gpt_icon":0},{"id":"2528189597","title":"Charles River price target raised to $118 from $101 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2528189597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528189597?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:15","pubTimestamp":1744888523,"startTime":"0","endTime":"0","summary":"Baird analyst Eric Coldwell raised the firm’s price target on Charles River (CRL) to $118 from $101 and keeps a Neutral rating on the shares. The f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-price-target-raised-to-118-from-101-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-price-target-raised-to-118-from-101-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRL","BK4588","BK4530","BK4121","LU0757428866.USD","LU0390134368.USD","BK4585","LU1815336091.USD"],"gpt_icon":0},{"id":"2528734072","title":"Charles River Laboratories International Inc : Baird Raises Target Price to $118 From $101","url":"https://stock-news.laohu8.com/highlight/detail?id=2528734072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528734072?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:06","pubTimestamp":1744862766,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0757428866.USD","LU0390134368.USD","BK4121","CRL","BK4588","BK4530","LU1815336091.USD","BK4585"],"gpt_icon":0},{"id":"2527452544","title":"Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527452544","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527452544?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:26","pubTimestamp":1744719960,"startTime":"0","endTime":"0","summary":"Charles River Laboratories CRL shares rallied 6.9% in the last trading session to close at $106.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 41.7% loss over the past four weeks.Charles River scored a strong price increase on investors’ optimism driven by the company’s impending first-quarter 2025 results, expected to release on May 8 before the market opens. In the last reported fourth quarter, both the top and bottom lines surpassed the Zacks Consensus Estimate by 2.7% and 6.4%, respectively.This medical research equipment and services provider is expected to post quarterly earnings of $2.06 per share in its upcoming report, which represents a year-over-year change of -9.3%. Revenues are expected to be $935.23 million, down 7.6% from the year-ago quarter.Charles River is part of the Zacks Medical Services industry. Alignment Healthcare ALHC, another stock in the same industry, cl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-charles-river-crl-122600959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALHC","CRL","BK4121","BK4585","BK4588","BK4539","BK4530","LU0390134368.USD","BK4154"],"gpt_icon":0},{"id":"2527413787","title":"Lisata Therapeutics Announces Research License with Catalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413787","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413787?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Catalent to evaluate certepetide with its SMARTag antibody-drug conjugate platform. “We are excited to partner with Lisata to investigate how certepetide and the SMARTag technology might be used together to make ADCs with enhanced functions,” stated Penelope Drake, Head of R&D, Bioconjugates at Catalent. “We are enthusiastic about the potential of this collaboration to deliver innovative treatment options.”Lisata Therapeutics is aclinical-stage pharmaceutical companydedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate,certepetide, is an investigational drug designed to activate a novel uptake","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lisata-therapeutics-announces-research-license-120000784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4530","SG9999011746.SGD","BK4563","BK4552","IE00BYQNZ168.SGD","BK4588","BK4565","TME","BK4007","BK4585","BK4535","CTLT","LU0359201612.USD","IE00B12V2V27.USD","LENZ","IE00BYTNYN87.SGD","BK4571","BK4139","LU2039709279.SGD","LU0359202008.SGD","BK4531","01698","LU1023057109.AUD","BK4108","LSTA","BK4526","BK4509"],"gpt_icon":0},{"id":"2527244413","title":"Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2527244413","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527244413?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Biopharma funding increased for the second consecutive year in 2024.Trial starts have fully returned to pre-pandemic levels.Improvement in productivity was driven by a success-rate increase in Phase III trials.\"Increases in funding, normalization of clinical trial starts, stabilization or acceleration of key cycle time drivers, and improvements in late-stage success and clinical productivity — all of which were observed in 2024 — demonstrate meaningful year-on-year progress in biopharmaceutical R&D,\" said Murray Aitken, executive director of the IQVIA Institute for Human Data Science. \"Although geopolitical, economic and other external ecosystem factors are increasing pressure on innovators, effective application of a range of productivity enablers has had a positive impact on the efficiency of clinical development.\". New drug approvals and launches. A total of 65 novel active s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stabilization-improvement-seen-multiple-key-120000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0198837287.USD","LU0130518102.USD","BK4585","LU1791710400.SGD","LU1989764748.USD","LU1989764664.SGD","LU0477156797.USD","LU0648001328.SGD","BK4530","LU1201861249.SGD","LU0528227936.USD","BK4121","LU0130517989.USD","LU1201861165.SGD","LU1791710582.SGD","LU0648000940.SGD","LU0477156953.USD","LU1261432733.SGD","BK4588","LU0130103400.USD","LU0882574055.USD","LU0130102774.USD","LU0980610538.SGD","IQV"],"gpt_icon":0},{"id":"2527814596","title":"Equity Markets Rise as Investors Respond to Tariff News","url":"https://stock-news.laohu8.com/highlight/detail?id=2527814596","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527814596?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:50","pubTimestamp":1744660222,"startTime":"0","endTime":"0","summary":"US benchmark equity indexes are on track to close higher on Monday as investors respond to the latest tariff updates.The Dow Jones Industrial Average gained 1.3% to 40,718.5, while the Nasdaq Composit","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":[".SPX","QID","SDS","CRL.AU","DDM","ISBC","VOO",".DJI","ESmain","UDOW","BK4581","SH","QLD","BK4121","NQmain","BK4530","SQQQ","IVV","BK4550","BK4547","MNQmain","SPY","PSQ","LU1861558580.USD","BK4585",".IXIC","BK4588","TQQQ","DOG","BK4543","BK4023","USAW.SI","USJW.SI","DXD","CRL","SDOW","DVA","BK4196","QQQ","NVIW.SI","TSYW.SI","DJX","BK4504","OEF","EQR","OEX","SSO"],"gpt_icon":1},{"id":"2527197306","title":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2527197306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527197306?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:00","pubTimestamp":1744646420,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500 .SPXTop PerformersPercent ChangeCharles River Laboratories International Inc CRL.N+5.1%Palantir Technologies Inc PLTR.OQ+4.1%Dell Technologies Inc DELL.N+3.1%Kenvue Inc KVUE.N+3.0%Mettler-Toledo International Inc MTD.N+2.9%Bottom PerformersPercent ChangeDaVita Inc DVA.N-3.8%Southwest Airlines Co LUV.N-3.7%Humana Inc HUM.N-3.6%Delta Air Lines Inc DAL.N-3.1%Broadcom Inc AVGO.OQ-2.8%As of 12:00 p.m., the S&P 500 .SPX gained 12.44 points, or 0.23%, to 5,375.80 and had posted one new 52-week high and no new lows.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL8N3QS1CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU2458330169.SGD","LU0323591593.USD","LU0965508806.USD","DELL","LU1721428933.USD","KVUE","LU1162221912.USD","HUM","LU0081259029.USD","LU1670711040.USD","IE00BKDWB100.SGD","PLTR","SG9999002232.USD","AVGO","IE00BLSP4239.USD","LU2237443382.USD","LU1548497426.USD","LU0345769128.USD","BK4530","LU0203201768.USD","IE00BJLML261.HKD","LU2125154778.USD","LU2250418816.HKD","SG9999015978.USD","LU0942090050.USD","LUV","SG9999015986.USD","BK4605","DVA","LU0719512351.SGD","LU1992135472.HKD","LU2458330243.SGD","LU0979878070.USD","LU0868494708.USD","MTD","SG9999001424.SGD","BK4196","IE00BFXG0V08.USD","LU0795875169.SGD","LU1992135399.USD","LU2413666426.HKD","DAL","CRL","LU2592432038.USD","BK4512","LU0208291251.USD","BK4548","IE00BK4W5L77.USD"],"gpt_icon":1},{"id":"2526525633","title":"FDA reducing animal testing presents overhang for Charles River, says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2526525633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526525633?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:45","pubTimestamp":1744325111,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Charles Rhyee reiterated a Hold rating and $179 price target on Charles River (CRL), saying the firm expects the FDA’s plan to pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-reducing-animal-testing-presents-overhang-for-charles-river-says-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-reducing-animal-testing-presents-overhang-for-charles-river-says-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0390134368.USD","BK4530","CRL","COWN","TD","BK4127","BK4585","BK4566","BK4207","BK4588","BK4121"],"gpt_icon":0},{"id":"2526516760","title":"Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526516760","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526516760?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:05","pubTimestamp":1744290300,"startTime":"0","endTime":"0","summary":"Bausch + Lomb BLCO shares ended the last trading session 13.9% higher at $12.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 29.2% loss over the past four weeks.Bausch + Lomb stock surged amid a broader market rebound following the Trump administration’s announcement of a temporary halt on reciprocal tariffs for most countries. The market is also upbeat about the company’s surrounding its impending first-quarter 2025 financial results, which is slated to release on April 30 before the opening bell.This company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $1.15 billion, up 4.4% from the year-ago quarter.Bausch + Lomb Corporation  : Free Stock Analysis Report. Charles River Laboratories International, Inc.  : Free Stock Analysis Report. This article originally published on Zac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-lomb-blco-moves-13-130500986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4530","BK4588","BK4585","BK4121","BK4198","LU0390134368.USD","BLCO","CRL","BK4007","BHC"],"gpt_icon":0},{"id":"2526216558","title":"Charles River price target lowered to $145 from $160 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2526216558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526216558?lang=en_us&edition=fundamental","pubTime":"2025-04-10 17:56","pubTimestamp":1744278968,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on Charles River (CRL) to $145 from $160 and keeps an Equal Weight rating on the shares as part of a Q1 ea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-price-target-lowered-to-145-from-160-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-price-target-lowered-to-145-from-160-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4530","BK4121","LU0390134368.USD","BK4585","BK4588","CRL"],"gpt_icon":0},{"id":"2526318811","title":"Positive Investment Outlook for IQVIA Holdings Amidst Market Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2526318811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526318811?lang=en_us&edition=fundamental","pubTime":"2025-04-10 01:05","pubTimestamp":1744218324,"startTime":"0","endTime":"0","summary":"IQVIA Holdings (IQV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Shlomo Rosenbaum from ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-investment-outlook-for-iqvia-holdings-amidst-market-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-investment-outlook-for-iqvia-holdings-amidst-market-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0882574055.USD","LU1989764748.USD","LU0130103400.USD","LU0198837287.USD","LU1201861165.SGD","BK4588","LU1791710400.SGD","LU0980610538.SGD","LU0528227936.USD","LU0648001328.SGD","LU0477156953.USD","LU1989764664.SGD","BK4121","BK4585","BK4530","LU1791710582.SGD","LU0648000940.SGD","LU0130102774.USD","LU0477156797.USD","LU1201861249.SGD","LU0130518102.USD","IQV","LU0130517989.USD","LU1261432733.SGD"],"gpt_icon":0},{"id":"2525289408","title":"Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2525289408","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525289408?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:45","pubTimestamp":1744116300,"startTime":"0","endTime":"0","summary":"Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April  08, 2025  (GLOBE NEWSWIRE) -- Outlook Therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057625/0/en/Outlook-Therapeutics-Announces-Acceptance-of-Biologics-License-Application-by-U-S-FDA-for-ONS-5010-as-a-Treatment-for-Wet-AMD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4612","LU0149725797.USD","LU2264538146.SGD","LU0889565833.HKD","IE00B5949003.HKD","LU0127658192.USD","BK4139","BK4156","BK4614","BK4121","IE0009356076.USD","LU1303367103.USD","GFS","LU0882574139.USD","LU2054465674.USD","LU0056508442.USD","LU1064131342.USD","LU1316542783.SGD","LU1242518931.SGD","LU1923623000.USD","BK4575","BK4605","LENZ","BK4006","CMC","CRL","LU1242518857.USD","LU1803068979.SGD","BK4585","LU0823434740.USD","LU0267386448.USD","BK4529","BK4554","BK4543","LU2458330169.SGD","UK","IE00BKVL7J92.USD","BK4588","BK4534","LU0971096721.USD","BK4233","LU0823421416.USD","LU1852331112.SGD","LU0719512351.SGD","BK4530","LU0198837287.USD","LU0642271901.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}